Kerri Fitzgerald

DocwireNews

A study published in the&nbsp;Journal of Clinical Oncology&nbsp;found that&nbsp;chemotherapy, hormone therapy, and&nbsp;ApoE&nbsp;genotype&nbsp;were associated with&nbsp;poorer cognitive function in older survivors of breast cancer.&nbsp;The researchers included 344 newly diagnosed non-metastatic breast cancer survivors&nbsp;and&nbsp;matched&nbsp;them with 347&nbsp;controls&nbsp;who did not have cancer. Patients were&nbsp;60 years&nbsp;or older, did not have&nbsp;dementia or neurologic disease, and&nbsp;were recruited between August 2010 and December 2015.&nbsp;Researchers collected data&nbsp;during pre-systemic treatment&nbsp;or&nbsp;control enrollment and at 12 and 24 months&nbsp;via&nbsp;biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuropsychological tests that measured attention, processing speed, and executive function (APE), as well as&nbsp;learning and memory (LM).&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Interesting article on treatment/ cognitive function/ and genotypes in older cancer patients. Great to see Dr. Huria of <a href="https://twitter.com/cityofhope?ref_src=twsrc%5Etfw">@cityofhope</a> on the team reporting this work. <a href="https://t.co/JXgaMnt3f9">https://t.co/JXgaMnt3f9</a> <a href="https://twitter.com/JCO_ASCO?ref_src=twsrc%5Etfw">@JCO_ASCO</a>
&mdash; Stacy W. Gray (@stacywgray) <a href="https://twitter.com/stacywgray/status/1049765865011466241?ref_src=twsrc%5Etfw">October 9, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Treatment was related to&nbsp;longitudinal cognition scores: Survivors who received chemotherapy&nbsp;had&nbsp;increasingly worse APE scores (P=0.05),&nbsp;and those initiating hormonal therapy&nbsp;had&nbsp;lower LM scores at 12 months (P=0.03).&nbsp;&nbsp;ApoE&nbsp;genotype impacted cognitive function as well: Only &epsilon;4+ survivors receiving hormone therapy had short-term decreases in adjusted LM scores (P=0.03).&nbsp;For APE, the&nbsp;three-way interaction was not significant (P=0.14), but scores were significantly lower for &epsilon;4+ survivors&nbsp;who received chemotherapy&nbsp;(&minus;0.40;&nbsp;95% CI, &minus;0.79-&minus;0.01) at 24 months than &epsilon;4+ controls (0.01; 95% CI, 0.16-0.18;&nbsp;P&lt;0.05).&nbsp;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Cancer-related cognitive outcomes among older breast cancer survivors in the Thinking and Living With Cancer (TLC) study <a href="https://t.co/TF0bAeK2RK">https://t.co/TF0bAeK2RK</a> <a href="https://twitter.com/hashtag/bcsm?src=hash&amp;ref_src=twsrc%5Etfw">#bcsm</a> <a href="https://twitter.com/hashtag/survonc?src=hash&amp;ref_src=twsrc%5Etfw">#survonc</a> <a href="https://t.co/tur5vxmo7x">pic.twitter.com/tur5vxmo7x</a>
&mdash; Journal of Clinical Oncology (@JCO_ASCO) <a href="https://twitter.com/JCO_ASCO/status/1050142702753464320?ref_src=twsrc%5Etfw">October 10, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Increasing age was associated with lower baseline scores on all cognitive measures (P&lt;0.001), and&nbsp;frailty was associated with baseline APE and self-reported decline (P&lt;0.001).&nbsp;&ldquo;These data could inform treatment decision making and survivorship care planning,&rdquo; the authors concluded.&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/postmenopausal-weight-loss-reduced/">Post-menopausal weight loss is linked to a reduced breast cancer risk.</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/nursing-home-breast-cancer/">Mortality is high in nursing home patients who undergo surgery for breast cancer.</a>&nbsp;Source:&nbsp;<a href="http://ascopubs.org/doi/full/10.1200/JCO.18.00140">Journal of Clinical Oncology</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Study Observes Cognitive Decline in Older Breast Cancer Survivors

Breast Cancer News

A study published in the Journal of Clinical Oncology found that chemotherapy, hormone therapy, and ApoE genotype were associated with poorer cognitive function in ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe